Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM H JOHNSTON JR.

Allopathic & Osteopathic Physicians Pediatrics

NPI
1740385764
CMS profile
33341
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$114.86

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $114.86 8

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM H JOHNSTON JR.

NPI 1740385764 · CMS profile ID 33341

Allopathic & Osteopathic Physicians / Pediatrics

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740385764?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740385764?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740385764?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1740385764?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $114.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $13.0307/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695634247 CMS
Sobi, Inc $23.8103/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698088291 CMS
Teva Pharmaceuticals USA, Inc. $10.9003/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697781447 CMS
Shire North American Group Inc $13.1202/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637848989 CMS
Shire North American Group Inc $12.3702/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637848991 CMS
Hologic, LLC $12.6102/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 649997201 CMS
Shire North American Group Inc $12.8401/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637848987 CMS
ARBOR PHARMACEUTICALS, INC. $16.1801/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697405236 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114.86 8
PY2023 $1,472.90 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $209,872.28 58
PY2024 Recipient $5,150.00 1
PY2024 Principal investigator $338,079.53 66
PY2023 Principal investigator $405,526.56 39
PY2022 Recipient $935.00 2
PY2022 Principal investigator $477,955.66 57
PY2021 Recipient $1,025.77 2
PY2021 Principal investigator $105,200.85 39
PY2020 Recipient $446.71 1
PY2020 Principal investigator $92,105.43 57
PY2019 Principal investigator $346,813.45 159

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $900.00 12/31/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
LIN-MD-64 Ph3 Ped FC and IBS-C Trial 6-17 (M21-567) No dispute reported 06/30/2026 1100765203
Principal investigator 1 Merck Sharp & Dohme LLC $1,352.60 12/31/2024 Non-covered Recipient Entity
Central Research Associates
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na ve Adults No dispute reported 06/30/2026 1136436852
Principal investigator 1 Merck Sharp & Dohme LLC $89,771.18 12/31/2024 Non-covered Recipient Entity
Central Research Associates
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136438067
Principal investigator 1 ModernaTX, Inc. $80.00 12/20/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187359
Principal investigator 1 GlaxoSmithKline, LLC. $53.34 12/06/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PROSPECTIVE, MULTI-COUNTRY, MULTICENTRE COHORT STUDY TO ASSESS THE D No dispute reported 06/30/2026 1127537772
Principal investigator 1 ModernaTX, Inc. $400.00 12/06/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187357
Principal investigator 1 Merck Sharp & Dohme LLC $72,272.75 11/22/2024 Non-covered Recipient Entity
Central Research Associates
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136438063
Principal investigator 1 GlaxoSmithKline, LLC. $52.06 11/20/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537766
Principal investigator 1 ModernaTX, Inc. $200.00 11/20/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187355
Principal investigator 1 ModernaTX, Inc. $473.85 11/15/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187351
Principal investigator 1 GlaxoSmithKline, LLC. $1,719.05 11/01/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127521894
Principal investigator 1 GlaxoSmithKline, LLC. $81.70 11/01/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537774
Principal investigator 1 ModernaTX, Inc. $40.00 11/01/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187353
Principal investigator 1 ModernaTX, Inc. $750.00 10/25/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187345
Principal investigator 1 ModernaTX, Inc. $160.00 10/25/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187347
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/25/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187349
Principal investigator 1 GlaxoSmithKline, LLC. $1,166.19 10/23/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 3B, OPEN-LABEL, MULTI-COUNTRY, MULTI-CENTRE, LONG-TERM FOLLOW- No dispute reported 06/30/2026 1127537776
Principal investigator 1 SANOFI US SERVICES INC. $45.00 10/23/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1155225880
Principal investigator 1 ModernaTX, Inc. $4,209.98 10/18/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187341
Principal investigator 1 SANOFI US SERVICES INC. $501.18 10/17/2024 Non-covered Recipient Entity
Q2Q UK LLP
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128705569
Principal investigator 1 SANOFI US SERVICES INC. $342.65 10/17/2024 Non-covered Recipient Entity
Q2Q UK LLP
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128705665
Principal investigator 1 SANOFI US SERVICES INC. $366.95 10/17/2024 Non-covered Recipient Entity
Q2Q UK LLP
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128705683
Principal investigator 1 SANOFI US SERVICES INC. $873.82 10/17/2024 Non-covered Recipient Entity
Q2Q UK LLP
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128705831
Principal investigator 1 SANOFI US SERVICES INC. $45.00 10/09/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1155225882
Principal investigator 1 ModernaTX, Inc. $200.00 10/04/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187343
Principal investigator 1 Merck Sharp & Dohme LLC $385.86 09/30/2024 Non-covered Recipient Entity
Central Research Associates
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136438378
Principal investigator 1 GlaxoSmithKline, LLC. $1,017.01 09/25/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537758
Recipient Eli Lilly and Company $5,150.00 09/24/2024 Covered Recipient Physician PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1137349967
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 09/20/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128721531
Principal investigator 1 ModernaTX, Inc. $1,184.62 09/18/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187279
Principal investigator 1 ModernaTX, Inc. $160.00 09/11/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187337
Principal investigator 1 ModernaTX, Inc. $40.00 09/11/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187339
Principal investigator 1 ModernaTX, Inc. $30,454.65 09/04/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187281
Principal investigator 1 SANOFI US SERVICES INC. $500.00 08/28/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128721537
Principal investigator 1 ModernaTX, Inc. $1,956.15 08/23/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187257
Principal investigator 1 GlaxoSmithKline, LLC. $3,295.30 08/16/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537770
Principal investigator 1 ModernaTX, Inc. $40.00 08/09/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187259
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 08/01/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128721533
Principal investigator 1 SANOFI US SERVICES INC. $500.00 08/01/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128721535
Principal investigator 1 ModernaTX, Inc. $80.00 07/26/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187221
Principal investigator 1 ModernaTX, Inc. $240.00 07/26/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187227
Principal investigator 1 ModernaTX, Inc. $80.00 07/26/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187229
Principal investigator 1 GlaxoSmithKline, LLC. $1,162.21 07/17/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537778
Principal investigator 1 ModernaTX, Inc. $1,719.22 07/17/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187225
Principal investigator 1 Merck Sharp & Dohme LLC $31,860.00 07/15/2024 Non-covered Recipient Entity
Central Research Associates
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na ve Adults No dispute reported 06/30/2026 1136436848
Principal investigator 1 SANOFI US SERVICES INC. $1,400.00 07/12/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128721539
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 07/12/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128721541
Principal investigator 1 GlaxoSmithKline, LLC. $807.82 07/03/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127521896
Principal investigator 1 GlaxoSmithKline, LLC. $2,222.28 07/03/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537760
Principal investigator 1 GlaxoSmithKline, LLC. $208.47 07/03/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537764
Principal investigator 1 ModernaTX, Inc. $4,288.95 07/03/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187223
Principal investigator 1 GlaxoSmithKline, LLC. $4,674.77 06/20/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537782
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 06/12/2024 Non-covered Recipient Entity
Central Research Associates Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128723613
Principal investigator 1 ModernaTX, Inc. $2,666.93 05/29/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187189
Principal investigator 1 GlaxoSmithKline, LLC. $2,904.29 05/22/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537780
Principal investigator 1 ModernaTX, Inc. $710.77 04/26/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187175
Principal investigator 1 ModernaTX, Inc. $8,608.27 04/10/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187177
Principal investigator 1 GlaxoSmithKline, LLC. $824.46 04/03/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127537756
Principal investigator 1 GlaxoSmithKline, LLC. $798.69 04/03/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127537784
Principal investigator 1 ModernaTX, Inc. $1,000.00 04/01/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187171
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/01/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187173
Principal investigator 1 GlaxoSmithKline, LLC. $1,455.89 03/08/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537762
Principal investigator 1 ModernaTX, Inc. $6,530.62 02/21/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187151
Principal investigator 1 ModernaTX, Inc. $12,235.05 02/02/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147187153
Principal investigator 1 Eli Lilly and Company $6,944.00 01/23/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1137356016
Principal investigator 1 Eli Lilly and Company $5,954.00 01/23/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1137356296
Principal investigator 1 GlaxoSmithKline, LLC. $1,111.95 01/12/2024 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127537768